A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Sep 28, 2023

Astellas Announces Personnel Change

TOKYO, September 28, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the following personnel change in its top management effective from...

Read more about Astellas Announces Personnel Change
Sep 22, 2023

PADCEV^® (enfortumab vedotin-ejfv) and KEYTRUDA^® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

– Trial results to be submitted for presentation at upcoming medical meeting –

TOKYO and BOTHELL, Wash. – September 22, 2023 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as...

Read more about PADCEV^® (enfortumab vedotin-ejfv) and KEYTRUDA^® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Sep 19, 2023

Astellas Highlights VEOZAH^TM (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society

Pooled analyses from pivotal Phase 3 SKYLIGHT^TMstudies provide new insights into fezolinetant for the treatment of moderate to severe VMS due to menopause

TOKYO, September 19, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) will share new pooled efficacy and safety analyses from the pivotal Phase 3 SKYLIGHT™ studies for VEOZAH™ (fezolinetant), its first-in-class treatment for moderate to severe vasomotor...

Read more about Astellas Highlights VEOZAH^TM (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society
Sep 19, 2023

China’s National Medical Products Administration Accepts New Drug Application for XTANDI^®(enzalutamide) in Metastatic Hormone-Sensitive Prostate Cancer

TOKYO, September 19, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted its New Drug...

Read more about China’s National Medical Products Administration Accepts New Drug Application for XTANDI^®(enzalutamide) in Metastatic Hormone-Sensitive Prostate Cancer
Sep 18, 2023

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY^TM (avacincaptad pegol intravitreal solution) for Geographic Atrophy

GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham

TOKYO, September 18, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive 24-month topline results from the Phase 3 GATHER2 clinical trial evaluating the efficacy and safety of IZERVAY™...

Read more about Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY^TM (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News